Australia markets closed

ImmuCell Corporation (ICCC)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
5.02-0.01 (-0.20%)
At close: 04:00PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
Total revenue
16,287
18,568
19,243
15,342
Cost of revenue
12,683
10,919
10,587
8,479
Gross profit
3,604
7,649
8,656
6,863
Operating expenses
Research development
4,378
4,494
4,169
4,355
Selling general and administrative
5,604
5,454
4,230
3,889
Total operating expenses
9,982
9,948
8,399
8,243
Operating income or loss
-6,378
-2,299
257.385
-1,380
Interest expense
402.385
340.878
306.518
412.687
Total other income/expenses net
353.469
8.246
-30.963
733.347
Income before tax
-6,298
-2,486
-69.127
-1,032
Income tax expense
4.789
7.672
9.165
-10.136
Income from continuing operations
-6,303
-2,494
-78.292
-1,022
Net income
-6,303
-2,494
-78.292
-1,022
Net income available to common shareholders
-6,303
-2,494
-78.292
-1,022
Basic EPS
-0.81
-0.32
-0.01
-0.14
Diluted EPS
-0.81
-0.32
-0.01
-0.14
Basic average shares
7,747
7,745
7,592
7,213
Diluted average shares
7,747
7,745
7,592
7,213